The Antiaging Trial That Just Won $1M From XPRIZE to Test in Humans
BiohackingThe XPRIZE Healthspan competition has been one of the most watched institutional bets in longevity science since its launch — $101 million allocated toward interventions that can demonstrably reverse functional aging in humans. AgelessRx has just crossed its second major milestone, winning $1 million to advance a one-year randomized controlled trial.
What Happened
AgelessRx was selected as one of 10 Milestone 2 awardees in the XPRIZE Healthspan competition, receiving $1 million toward a fully powered human trial evaluating muscle, cognitive, and immune function. The trial is planned to run from 2026 through 2029, enrolling approximately 186 adults aged 50 to 90, overseen by the University of Utah’s Data Coordinating Center with UC San Diego’s Stein Institute handling biomarker coordination.
The intervention being tested is a six-component multi-modal protocol: low-dose naltrexone, metformin, NAD+, vitamin B12, low-dose rapamycin, and glutathione, paired with exercise and guided meditation.
The milestone win follows the completion of a 90-day pilot study that enrolled 26 adults aged 60 to 80, with 18 completing the randomized, placebo-controlled protocol. The specific results of the pilot haven’t been detailed publicly beyond noting it evaluated muscle, cognitive, and immune function.
Why It Matters
The XPRIZE framework is significant not just as a funding source but as institutional validation of a multi-modal approach to aging. Most clinical longevity research targets single compounds — rapamycin alone, metformin alone — because single-drug trials are cleaner to design and easier to publish. AgelessRx’s protocol combines six components, plus exercise and meditation, against three functional outcome categories simultaneously.
This design won’t produce a clean answer about which component drives which result. That’s a weakness for mechanism research. It’s a strength for practical intervention research: real longevity stacks are multi-modal, and the question of whether a combined protocol produces meaningful functional improvements in a diverse aging population is clinically relevant even if the mechanistic attribution remains unclear.
The selection of muscle, cognitive, and immune function as the three measured domains reflects a shift in longevity science toward functional endpoints rather than biomarker endpoints alone. Aging clocks and methylation markers are useful, but XPRIZE requires demonstrating that people actually move better, think better, and fight off infections better — endpoints that translate directly to health outcomes.
The So What
For practitioners tracking longevity science: the $1 million XPRIZE milestone award doesn’t validate the AgelessRx protocol as effective — that’s what the 2026-2029 trial is designed to test. What it validates is the trial design as competitive within a rigorous institutional framework. If the one-year trial produces meaningful results in muscle, cognitive, and immune function across a population aged 50-90, it would represent the strongest human evidence yet for a combined low-dose intervention approach to functional aging. The full prize of up to $81 million is expected to be awarded in 2030. Watch this trial.
Source: Longevity.Technology
Content created with AI assistance and reviewed for accuracy.
Join the conversation
Stack Insiders is our free community for readers who want to go deeper — share resources, ask questions, and connect with others across every vertical we cover.
Join Stack Insiders →